<DOC>
	<DOCNO>NCT02172950</DOCNO>
	<brief_summary>This multicenter , open-label , phase 3 extension study investigate safety efficacy rVIII‑SingleChain prophylaxis on‑demand treatment bleed episode least 200 previously treat patient ( PTPs ) severe congenital hemophilia A previous exposure FVIII product achieve least 100 exposure day ( EDs ) rVIII-SingleChain study , well least 50 previously untreated patient ( PUPs ) previous exposure FVIII product achieve least 50 EDs rVIII-SingleChain study . A substudy ( open PTPs PUPs ) investigate use rVIII-SingleChain surgery .</brief_summary>
	<brief_title>An Open-label Safety Efficacy Study Recombinant FVIII Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>PTPs : Males age diagnose severe congenital hemophilia A ( FVIII activity level &lt; 1 % ) participate previous CSLsponsored clinical study rVIIISingleChain . Males 0 &lt; 65 year age diagnose severe congenital hemophilia A ( FVIII activity level &lt; 1 % ) , least 50 EDs FVIII product , currently enrol CSLsponsored clinical study rVIIISingleChain . PUPs : Males 0 &lt; 18 year diagnose severe congenital hemophilia A ( FVIII activity level &lt; 1 % ) No prior exposure Factor VIII product ( exception shortterm use blood product ) . Known suspected hypersensitivity rVIII‑SingleChain excipients rVIII‑SingleChain Chinese hamster ovary ( CHO ) proteins . Currently receive therapy permit study . Serum creatinine &gt; 2 x upper limit normal , alanine aminotransferase aspartate aminotransferase &gt; 5 x upper limit normal Screening ( specify ) Any firstorder family ( eg , sibling ) history FVIII inhibitor For PTPs roll directly CSLsponsored clinical study rVIIISingleChain : history current FVIII inhibitor</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>